

**SUMMARY OF CHANGES:**

**INSTRUMENT NOS. 52 to 69 of 2020**

Statements of Principles Nos. 52 to 69 of 2020 were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 28 August 2020. The day of commencement as specified in each of these Instruments is 28 September 2020.

These Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the *Legislation Act 2003* (Legislation Act). In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument's registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from [http://www.legislation.gov.au](http://www.comlaw.gov.au).

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Statement of Principles, are available in accordance with the *Veterans' Entitlements Act 1986* (the VEA), on written request from the RMA Secretariat.

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the Statement of Principles template which commenced in 2015. This document is available on the Authority's website at <http://www.rma.gov.au>.

For further information contact:

The Registrar

Repatriation Medical Authority

GPO Box 1014

Brisbane Qld 4001

T +61 7 3815 9404

F +61 7 3815 9412

E info@rma.gov.au

4 September 2020

**SUMMARY OF CHANGES**

|  |  |  |  |
| --- | --- | --- | --- |
| **Instr. No.** | **Title** | **Date of Commencement** | **ICD-10-AM Code** |
| **REPEALS** | | | |
|  |  |  |  |
| 52 & 53/2020 | non-aneurysmal aortic atherosclerotic disease | 28/09/2020 | I70.0 |
|  |  |  |  |
| 54 & 55/2020 | carotid artery disease | 28/09/2020 | I65.2, I70.8, I72.0, I77.0 |
|  |  |  |  |
| 56 & 57/2020 | renal artery atherosclerotic disease | 28/09/2020 | I70.1 |
|  |  |  |  |
| 58 & 59/2020 | aplastic anaemia | 28/09/2020 | D61.1, D61.2, D61.3, D61.8 |
|  |  |  |  |
| 60 & 61/2020 | pure red cell aplasia | 28/09/2020 | D60 |
|  |  |  |  |
| 62 & 63/2020 | chloracne | 28/09/2020 | N/A |
|  |  |  |  |
| 64 & 65/2020 | chronic pancreatitis | 28/09/2020 | K86.0, K86.1 |
|  |  |  |  |
| 66 & 67/2020 | malignant neoplasm of bone and articular cartilage | 28/09/2020 | C40, C41 |
|  |  |  |  |
| **AMENDMENTS** | | | |
|  |  |  |  |
| 68 & 69/2020 | trochanteric bursitis and gluteal tendinopathy | 28/09/2020 | M70.6 |
|  |  |  |  |

Note:

* The investigation concerning 'carotid arterial disease' has resulted in the determination of Statements of Principles concerning carotid artery disease.
* The investigation concerning 'aplastic anaemia' has resulted in the determination of Statements of Principles concerning aplastic anaemia and pure red cell aplasia.

| **SUMMARY OF CHANGES** | | | | |
| --- | --- | --- | --- | --- |
| 52 & 53/2020 | | non-aneurysmal aortic atherosclerotic disease | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 7 May 2019 concerning *non-aneurysmal aortic atherosclerotic disease* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 52/2020)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'non-aneurysmal aortic atherosclerotic disease' in subsection 7(2); * revising ICD-10-AM codes for 'non-aneurysmal aortic atherosclerotic disease' in subsection 7(3); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * new factors in subsections 9(3) and 9(21) concerning being obese; * revising the factors in subsections 9(4) and 9(22) concerning dyslipidaemia, by the inclusion of a note; * new factors in subsections 9(5) and 9(23) concerning smoking of tobacco products, where smoking has not permanently ceased; * new factors in subsections 9(6) and 9(24) concerning smoking of tobacco products, where smoking has permanently ceased; * new factors in subsections 9(7) and 9(25) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; * new factors in subsections 9(8) and 9(26) concerning exposure to second-hand smoke, where that exposure has permanently ceased; * new factors in subsections 9(10) and 9(28) concerning inability to undertake physical activity; * new factors in subsections 9(11) and 9(29) concerning chronic kidney disease; * revising the factors in subsections 9(13) and 9(31) concerning receiving ionising radiation, by the inclusion of a note; * new factors in subsections 9(14) and 9(32) concerning inability to consume fruit and vegetables; * new factors in subsections 9(15) and 9(33) concerning infection with human immunodeficiency virus or hepatitis C virus; * new factors in subsections 9(17) and 9(35) concerning autoimmune disease; * new factors in subsections 9(18) and 9(36) concerning having a clinically significant disorder of mental health as specified; * deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(5) and 9(23) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(6) and 9(24) concerning smoking of tobacco products, where smoking has permanently ceased; * deleting the factors concerning being in an atmosphere with a visible tobacco smoke haze in an enclosed space, as these are now covered by the factors in subsections 9(7) and 9(25) concerning exposure to second-hand smoke, where that exposure has not permanently ceased and the factors in subsections 9(8) and 9(26) concerning exposure to second-hand smoke, where that exposure has permanently ceased; * deleting the factors concerning chronic renal disease, as these are now covered by the factors in subsections 9(11) and 9(29) concerning chronic kidney disease; * deleting the factors concerning having clinically significant depressive disorder, as these are now covered by the factors in subsections 9(18) and 9(36) concerning having a clinically significant disorder of mental health as specified; * new definitions of 'abnormality of kidney structure or function', 'being exposed to second-hand smoke', 'being obese', 'BMI', 'chronic kidney disease', 'clinically significant disorder of mental health as specified', 'MET', 'MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'dyslipidaemia' and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and * deleting the definitions of 'chronic renal disease', 'clinically significant', 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'.   ***For BoP SoP*** ***(Instrument No. 53/2020)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a date of effect for the Instrument in section 2; * revising the definition of 'non-aneurysmal aortic atherosclerotic disease' in subsection 7(2); * revising ICD-10-AM codes for 'non-aneurysmal aortic atherosclerotic disease' in subsection 7(3); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factors in subsections 9(3) and 9(14) concerning dyslipidaemia, by the inclusion of a note; * new factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has not permanently ceased; * new factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; * new factors in subsections 9(6) and 9(17) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; * new factors in subsections 9(7) and 9(18) concerning exposure to second-hand smoke, where that exposure has permanently ceased; * new factors in subsections 9(9) and 9(20) concerning chronic kidney disease; * revising the factors in subsections 9(11) and 9(22) concerning receiving ionising radiation, by the inclusion of a note; * deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; * new definitions of 'abnormality of kidney structure or function', 'being exposed to second-hand smoke', 'chronic kidney disease', 'MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and * deleting the definitions of 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or equivalent thereof in other tobacco products'.   **The determining of these Instruments finalises the investigation in relation to *non-aneurysmal aortic atherosclerotic disease* as advertised in the Government Notices Gazette of 7 May 2019.** | |
| 54 & 55/2020 | carotid artery disease | | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning *carotid arterial disease* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 54/2020)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; * new definition of 'carotid artery disease' in subsection 7(2); * revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * new factors in subsections 9(3) and 9(28) concerning being obese; * revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; * new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; * new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; * new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; * new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; * new factor in subsection 9(10) concerning inability to undertake physical activity, for clinical onset; * new factors in subsections 9(11) and 9(36) concerning chronic kidney disease; * revising the factors in subsections 9(13) and 9(38) concerning receiving ionising radiation, by the inclusion of a note; * new factors in subsections 9(14) and 9(39) concerning inability to consume fruit and vegetables; * new factors in subsections 9(15) and 9(40) concerning infection with human immunodeficiency virus or hepatitis C virus; * new factors in subsections 9(17) and 9(42) concerning infection of the affected artery with a bacterial or fungal organism; * new factors in subsections 9(18) and 9(43) concerning autoimmune disease of the affected artery; * revising the factors in subsections 9(20) and 9(45) concerning being exposed to arsenic, by the inclusion of a note; * new factors in subsections 9(21) and 9(46) concerning obstructive sleep apnoea; * revising the factors in subsections 9(22) and 9(47) concerning being postpartum, for dissection of the internal carotid artery only; * revising the factors in subsections 9(23) and 9(48) concerning trauma to the affected segment of the artery, for aneurysm, dissection or arteriovenous fistula only; * revising the factors in paragraphs 9(24)(a) and 9(49)(a) concerning trauma to the neck or the base of the skull, for dissection only; * new factors in paragraphs 9(24)(b) and 9(49)(b) concerning taking a fluoroquinolone antibiotic, for dissection only; * revising the factors in subsections 9(25) and 9(50) concerning taking a drug, for aneurysm or dissection of the common or internal carotid artery only; * revising the factor in subsection 9(35) concerning inability to undertake physical activity, for clinical worsening; * deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; * deleting the factors concerning being in an atmosphere with a visible tobacco smoke haze in an enclosed space, as these are now covered by the factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased and the factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; * deleting the factors concerning chronic renal disease, as these are now covered by the factors in subsections 9(11) and 9(36) concerning chronic kidney disease; * deleting the factors concerning undergoing therapy with BCG vaccine, for aneurysm of the common, internal or external carotid artery only, as these are now covered by the factors in subsections 9(17) and 9(42) concerning infection of the affected artery with a bacterial or fungal organism; * deleting the factors concerning having infective or noninfective vasculitis of the affected segment of the artery, as these are now covered by the factors in in subsections 9(15) and 9(40) concerning infection with human immunodeficiency virus or hepatitis C virus, the factors in subsections 9(17) and 9(42) concerning infection of the affected artery with a bacterial or fungal organism and the factors in subsections 9(18) and 9(43) concerning autoimmune disease of the affected artery; * new definitions of 'abnormality of kidney structure or function', 'being exposed to second-hand smoke', 'being obese', 'BMI', 'chronic kidney disease', 'MRCA', 'pack-year of tobacco products', 'specified list of drugs' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'being exposed to arsenic as specified', 'dyslipidaemia', 'relevant service' by the inclusion of a note, 'trauma to the affected segment of the artery' and 'trauma to the neck or the base of the skull' in Schedule 1 - Dictionary; and * deleting the definitions of 'a 'a drug from the specified list', 'chronic renal disease', 'hyperhomocysteinaemia', 'pack-years of cigarettes, or the equivalent thereof in other tobacco products' and 'undergoing therapy with BCG vaccine'.   ***For BoP SoP*** ***(Instrument No. 55/2020)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a date of effect for the Instrument in section 2; * revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; * new definition of 'carotid artery disease' in subsection 7(2); * revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factors in subsections 9(3) and 9(22) concerning dyslipidaemia, by the inclusion of a note; * new factors in subsections 9(4) and 9(23) concerning smoking of tobacco products, where smoking has not permanently ceased; * new factors in subsections 9(5) and 9(24) concerning smoking of tobacco products, where smoking has permanently ceased; * new factors in subsections 9(6) and 9(25) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; * new factors in subsections 9(7) and 9(26) concerning exposure to second-hand smoke, where that exposure has permanently ceased; * new factors in subsections 9(9) and 9(28) concerning chronic kidney disease; * revising the factors in subsections 9(11) and 9(30) concerning receiving ionising radiation, by the inclusion of a note; * new factors in subsections 9(12) and 9(31) concerning infection with human immunodeficiency virus or hepatitis C virus; * new factors in subsections 9(13) and 9(32) concerning infection of the affected artery with a bacterial or fungal organism; * new factors in subsections 9(14) and 9(33) concerning autoimmune disease of the affected artery; * revising the factors in subsections 9(16) and 9(35) concerning being postpartum, for dissection of the internal carotid artery only; * revising the factors in subsections 9(17) and 9(36) concerning trauma to the affected segment of the artery, for aneurysm, dissection or arteriovenous fistula only; * revising the factors in subsections 9(18) and 9(37) concerning trauma to the neck or the base of the skull, for dissection only; * revising the factors in subsections 9(19) and 9(38) concerning taking a drug, for aneurysm or dissection of the common or internal carotid artery only; * deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(4) and 9(23) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(5) and 9(24) concerning smoking of tobacco products, where smoking has permanently ceased; * deleting the factors concerning chronic renal disease, as these are now covered by the factors in subsections 9(9) and 9(28) concerning chronic kidney disease; * deleting the factors concerning undergoing therapy with BCG vaccine, for aneurysm of the common, internal or external carotid artery only, as these are now covered by the factors in subsections 9(13) and 9(32) concerning infection of the affected artery with a bacterial or fungal organism; * deleting the factors concerning having infective or noninfective vasculitis of the affected segment of the artery, as these are now covered by the factors in subsections 9(12) and 9(31) concerning infection with human immunodeficiency virus or hepatitis C virus, the factors in subsections 9(13) and 9(32) concerning infection of the affected artery with a bacterial or fungal organism and the factors in subsections 9(14) and 9(33) concerning autoimmune disease of the affected artery; * new definitions of 'abnormality of kidney structure or function', 'being exposed to second-hand smoke', 'chronic kidney disease', 'MRCA', 'pack-year of tobacco products', 'specified list of drugs' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'dyslipidaemia', 'relevant service' by the inclusion of a note, 'trauma to the affected segment of the artery' and 'trauma to the neck or the base of the skull' in Schedule 1 - Dictionary; and * deleting the definitions of 'a drug from the specified list', 'chronic renal disease', 'hyperhomocysteinaemia', ' pack-years of cigarettes, or the equivalent thereof in other tobacco products' and 'undergoing therapy with BCG vaccine'.   **The determining of these Instruments finalises the investigation in relation to *carotid arterial disease* as advertised in the Government Notices Gazette of 29 October 2019.** |
| 56 & 57/2020 | renal artery atherosclerotic disease | | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 6 November 2018 concerning *renal artery atherosclerotic disease* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 56/2020)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'renal artery atherosclerotic disease' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * new factors in subsections 9(3) and 9(18) concerning being obese; * revising the factors in subsections 9(4) and 9(19) concerning dyslipidaemia, by the inclusion of a note; * new factors in subsections 9(5) and 9(20) concerning smoking of tobacco products, where smoking has not permanently ceased; * new factors in subsections 9(6) and 9(21) concerning smoking of tobacco products, where smoking has permanently ceased; * new factors in subsections 9(7) and 9(22) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; * new factors in subsections 9(8) and 9(23) concerning exposure to second-hand smoke, where that exposure has permanently ceased; * new factors in subsections 9(10) and 9(25) concerning inability to undertake physical activity; * new factors in subsections 9(11) and 9(26) concerning chronic kidney disease; * revising the factors in subsections 9(13) and 9(28) concerning receiving ionising radiation, by the inclusion of a note; * new factors in subsections 9(14) and 9(29) concerning inability to consume fruit and vegetables; * new factors in subsections 9(15) and 9(30) concerning periodontitis; * revising the factor in subsection 9(31) concerning being treated with an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker, for clinical worsening only; * deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(5) and 9(20) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(6) and 9(21) concerning smoking of tobacco products, where smoking has permanently ceased; * new definitions of 'abnormality of kidney structure or function', 'being exposed to second-hand smoke', 'being obese', 'BMI', 'chronic kidney disease', 'MET', 'MRCA', 'pack-year of tobacco products' and 'VEA' in * Schedule 1 - Dictionary; * revising the definitions of 'dyslipidaemia' and 'relevant service' by the inclusion of a note, in Schedule 1 - Dictionary; and * deleting the definitions of 'a course of therapeutic radiation', 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'.   ***For BoP SoP*** ***(Instrument No. 57/2020)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a date of effect for the Instrument in section 2; * revising the definition of 'renal artery atherosclerotic disease' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factors in subsections 9(3) and 9(13) concerning dyslipidaemia, by the inclusion of a note; * new factors in subsections 9(4) and 9(14) concerning smoking of tobacco products, where smoking has not permanently ceased; * new factors in subsections 9(5) and 9(15) concerning smoking of tobacco products, where smoking has permanently ceased; * new factors in subsections 9(6) and 9(16) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; * new factors in subsections 9(7) and 9(17) concerning exposure to second-hand smoke, where that exposure has permanently ceased; * revising the factors in subsections 9(10) and 9(20) concerning receiving ionising radiation, by the inclusion of a note; * revising the factor in subsection 9(21) concerning treatment with with an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker, for clinical worsening only; * deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(4) and 9(14) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(5) and 9(15) concerning smoking of tobacco products, where smoking has permanently ceased; * new definitions of 'being exposed to second-hand smoke', 'MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note, in Schedule 1 - Dictionary; and * deleting the definitions of 'a course of therapeutic radiation', 'hyperhomocysteinaemia', and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'.   **The determining of these Instruments finalises the investigation in relation to *renal artery atherosclerotic disease* as advertised in the Government Notices Gazette of 6 November 2018.** |
| 58 & 59/2020 | aplastic anaemia | | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning *aplastic anaemia* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 58/2020)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'aplastic anaemia' in subsection 7(2); * revising ICD-10-AM codes for 'aplastic anaemia' in subsection 7(3); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factor in subsection 9(2) concerning being treated with a drug specified in the Schedule 2 - Drugs, for clinical onset only; * new factor in subsection 9(3) concerning being treated with a drug, for clinical onset only; * revising the factor in subsection 9(4) concerning being treated with a non-aspirin, nonsteroidal, anti-inflammatory drug, for clinical onset only; * revising the factor in subsection 9(6) concerning being exposed to benzene, for clinical onset only; * new factor in subsection 9(7) concerning inhaling, ingesting or having cutaneous contact with a herbicide or insecticide, for clinical onset only; * revising the factor in subsection 9(8) concerning acute hepatitis, for clinical onset only; * revising the factor in subsection 9(10) concerning autoimmune diseases, for clinical onset only; * new factor in subsection 9(11) concerning haematological malignancies, for clinical onset only; * revising the factor in subsection 9(12) concerning thymoma or thymic carcinoma, for clinical onset only; * new factor in subsection 9(13) concerning infection with parvovirus B19 or acute infectious mononucleosis, for clinical onset only; * new factor in subsection 9(14) concerning being pregnant, for clinical worsening; * deleting the factor concerning inhaling, ingesting or having cutaneous contact with a pesticide, as this is now covered by the factor in subsection 9(7) concerning inhaling, ingesting or having cutaneous contact with a herbicide or insecticide; * deleting the factor concerning undergoing a course of therapeutic radiation for ankylosing spondylitis; * new definitions of 'MRCA', 'specified list of haematological malignancies', 'specified list of herbicides and insecticides' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'being exposed to benzene as specified', 'relevant service' by the inclusion of a note and 'specified list of autoimmune diseases' in Schedule 1 - Dictionary; * new table of specified drugs in Schedule 2 - Drugs; and * deleting the definitions of 'a drug or a drug from a class of drugs from the specified list', 'a nonsteroidal anti-inflammatory drug from the specified list', 'inhaling, ingesting or having cutaneous contact with' and 'specified list of pesticides'.   ***For BoP SoP*** ***(Instrument No. 59/2020)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'aplastic anaemia' in subsection 7(2); * revising ICD-10-AM codes for 'aplastic anaemia' in subsection 7(3); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factor in subsection 9(2) concerning being treated with a drug specified in the Schedule 2 - Drugs, for clinical onset only; * new factor in subsection 9(3) concerning being treated with a drug, for clinical onset only; * revising the factor in subsection 9(4) concerning being exposed to benzene, for clinical onset only; * new factor in subsection 9(5) concerning inhaling, ingesting or having cutaneous contact with an organophosphate insecticide, for clinical onset only; * revising the factor in subsection 9(6) concerning acute hepatitis, for clinical onset only; * revising the factor in subsection 9(8) concerning autoimmune diseases, for clinical onset only; * new factor in subsection 9(9) concerning lymphocytic leukaemia/small lymphocytic lymphoma or T-cell large granular lymphocytic leukaemia, for clinical onset only; * revising the factor in subsection 9(10) concerning thymoma or thymic carcinoma, for clinical onset only; * new factor in subsection 9(11) concerning being pregnant, for clinical worsening; * deleting the factor concerning undergoing a course of therapeutic radiation for ankylosing spondylitis; * new definitions of 'MRCA' and 'VEA', in Schedule 1 - Dictionary; * revising the definitions of 'being exposed to benzene as specified', 'relevant service' by the inclusion of a note and 'specified list of autoimmune diseases' in Schedule 1 - Dictionary; * new table of specified drugs in Schedule 2 - Drugs; and * deleting the definition of 'a drug or a drug from a class of drugs from the specified list'.   On 16 April 2020, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instrument and the medical-scientific material considered by the Authority. This letter emphasised the deletion of the factor relating to *undergoing a course of therapeutic radiation for ankylosing spondylitis* within the six months before the clinical onset of aplastic anaemia. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instrument prior to its determination. No submissions were received for consideration by the Authority. Non-substantial changes were made to the proposed Instrument following this consultation process.  **The determining of these Instruments finalises the investigation in relation to *aplastic anaemia* as advertised in the Government Notices Gazette of 29 October 2019.** |
| 60 & 61/2020 | pure red cell aplasia | | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning *aplastic anaemia* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence available to the Authority. On consideration of the sound medical-scientific evidence the Authority decided to determine separate Statements of Principles for aplastic anaemia and pure red cell aplasia. The available evidence for pure red cell aplasia supports a number of risk factors being causally associated with the clinical onset and worsening of this disease. The evidence also indicates that red cell aplasia is a separate disease from aplastic anaemia, with a different pathogenesis in the bone marrow.  **The determining of these Instruments finalises the investigation in relation to *aplastic anaemia* as advertised in the Government Notices Gazette of 29 October 2019.** |
| 62 & 63/2020 | chloracne | | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 7 May 2019 concerning *chloracne* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  ***For RH SoP*** ***(Instrument No. 62/2020)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'chloracne' in subsection 7(2); * revising the factors in subsections 9(1) and 9(2) concerning inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon; * deleting the factors concerning inhaling, ingesting or having cutaneous contact with a polychlorodibenzofuran (PCDF), as these are now covered by the factors in subsections 9(1) and 9(2) concerning inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon; * deleting the factors concerning inhaling, ingesting or having cutaneous contact with a polychlorodibenzo-para-dioxin (PCDD), as these are now covered by the factors in subsections 9(1) and 9(2) concerning inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon; * deleting the factors concerning inhaling, ingesting or having cutaneous contact with a specified chemical agent, as these are now covered by the factors in subsections 9(1) and 9(2) concerning inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon; * deleting the factors concerning inhaling, ingesting or having cutaneous contact with dihydrotrifluoromethylphenyl benzothiopyranopyrazolone; * new definitions of 'MRCA', 'polychlorodibenzofurans (PCDFs) as specified', 'polychlorodibenzo-para-dioxins (PCDDs) as specified', 'specified list of polyhalogenated aromatic hydrocarbons' and 'VEA' in Schedule 1 - Dictionary; * revising the definition of 'relevant service' by the inclusion of a note, in Schedule 1 - Dictionary; and * deleting the definitions of 'a polychlorodibenzofuran (PCDF) from the specified list', 'a polychlorodibenzo-para-dioxin (PCDD) from the specified list', 'a polyhalogenated aromatic hydrocarbon from the specified list', 'a specified chemical agent' and 'inhaling, ingesting or having cutaneous contact with'.   ***For BoP SoP*** ***(Instrument No. 63/2020)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'chloracne' in subsection 7(2); * revising the factors in subsections 9(1) and 9(2) concerning inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon; * deleting the factors concerning inhaling, ingesting or having cutaneous contact with a polychlorodibenzofuran (PCDF), as these are now covered by the factors in subsections 9(1) and 9(2) concerning inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon; * deleting the factors concerning inhaling, ingesting or having cutaneous contact with a polychlorodibenzo-para-dioxin (PCDD), as these are now covered by the factors in subsections 9(1) and 9(2) concerning inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon; * deleting the factors concerning inhaling, ingesting or having cutaneous contact with a specified chemical agent, as these are now covered by the factors in subsections 9(1) and 9(2) concerning inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon; * new definitions of 'MRCA', 'polychlorodibenzofurans (PCDFs) as specified', 'polychlorodibenzo-para-dioxins (PCDDs) as specified', 'specified list of polyhalogenated aromatic hydrocarbons' and 'VEA' in Schedule 1 - Dictionary; * revising the definition of 'relevant service' by the inclusion of a note, in Schedule 1 - Dictionary; and * deleting the definitions of 'a polychlorodibenzofuran (PCDF) from the specified list', 'a polychlorodibenzo-para-dioxin (PCDD) from the specified list', 'a polyhalogenated aromatic hydrocarbon from the specified list', 'a specified chemical agent' and 'inhaling, ingesting or having cutaneous contact with'.   On 16 April 2020, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instrument and the medical-scientific material considered by the Authority. This letter emphasised the deletion of factors relating to *inhaling, ingesting or having cutaneous contact with dihydrotrifluoromethylphenyl benzothiopyranopyrazolone* from the reasonable hypothesis Statement of Principles. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instrument prior to its determination. No submissions were received for consideration by the Authority. Non-substantial changes were made to the proposed Instrument following this consultation process.  **The determining of these Instruments finalises the investigation in relation to *chloracne* as advertised in the Government Notices Gazette of 7 May 2019.** |
| 64 & 65/2020 | chronic pancreatitis | | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 6 November 2018 concerning *chronic pancreatitis* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 64/2020)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'chronic pancreatitis' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factor in subsection 9(1) concerning smoking of tobacco products, for clinical onset only; * revising the factor in subsection 9(2) concerning consumption of alcohol, for clinical onset only; * revising the factor in subsection 9(3) concerning undergoing therapeutic radiation for cancer, for clinical onset only; * revising the factor in subsection 9(7) concerning hypertriglyceridaemia, for clinical onset only; * revising the factor in subsection 9(9) concerning chronic renal failure, for clinical onset only; * deleting the factor concerning receiving ionising radiation; * new definitions of 'chronic renal failure', 'MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1 - Dictionary; * revising the definition of 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and * deleting the definitions of 'a course of therapeutic radiation', 'cumulative equivalent dose' and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'.   ***For BoP SoP*** ***(Instrument No. 65/2020)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'chronic pancreatitis' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factor in subsection 9(1) concerning smoking of tobacco products, for clinical onset only; * revising the factor in subsection 9(2) concerning consumption of alcohol, for clinical onset only; * revising the factor in subsection 9(3) concerning undergoing therapeutic radiation for cancer, for clinical onset only; * revising the factor in subsection 9(7) concerning hypertriglyceridaemia, for clinical onset only; * deleting the factor concerning receiving ionising radiation; * new definitions of 'MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1 - Dictionary; * revising the definition of 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and * deleting the definitions of 'a course of therapeutic radiation', 'cumulative equivalent dose' and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'.   On 16 April 2020, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instrument and the medical-scientific material considered by the Authority. This letter emphasised the deletion of the factor relating to *having received a cumulative equivalent dose of at least 10 sieverts of ionising radiation to the pancreas*, at least one year before the clinical onset of chronic pancreatitis. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instrument prior to its determination. No submissions were received for consideration by the Authority. Non-substantial changes were made to the proposed Instrument following this consultation process  **The determining of these Instruments finalises the investigation in relation to *chronic pancreatitis* as advertised in the Government Notices Gazette of 6 November 2018.** |
| 66 & 67/2020 | malignant neoplasm of bone and articular cartilage | | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 6 November 2018 concerning *malignant neoplasm of bone and articular cartilage* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 66/2020)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'malignant neoplasm of bone and articular cartilage' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factor in subsection 9(1) concerning receiving ionising radiation, by the inclusion of a note, for clinical onset only; * revising the factor in subsection 9(2) concerning Paget's disease of bone, for clinical onset only; * new factor in subsection 9(3) concerning osteonecrosis of the metaphysis or diaphysis of bone, for clinical onset only; * revising the factor in subsection 9(4) concerning chronic osteomyelitis, for clinical onset only; * new factor in subsection 9(5) concerning giant cell tumour of bone, for clinical onset only; * revising the factor in subsection 9(6) concerning stem cell or bone marrow transplantation, for clinical onset only; * new factor in subsection 9(7) concerning taking growth hormone, for clinical onset only; * new factor in subsection 9(8) concerning taking an anthracycline chemotherapeutic agent, for clinical onset only; * new factor in subsection 9(9) concerning taking denosumab, for clinical onset only; * deleting the factor concerning bone infarct, as this is now covered by the factor in subsection 9(3) concerning osteonecrosis of the metaphysis or diaphysis of bone; * new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and * revising the definition of 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary.   ***For BoP SoP*** ***(Instrument No. 67/2020)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'malignant neoplasm of bone and articular cartilage' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factor in subsection 9(1) concerning receiving ionising radiation, by the inclusion of a note, for clinical onset only; * revising the factor in subsection 9(2) concerning Paget's disease of bone, for clinical onset only; * revising the factor in subsection 9(3) concerning chronic osteomyelitis, for clinical onset only; * new factor in subsection 9(4) concerning giant cell tumour of bone, for clinical onset only; * new factor in subsection 9(5) concerning taking an anthracycline chemotherapeutic agent, for clinical onset only; * new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and * revising the definition of 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary.   **The determining of these Instruments finalises the investigation in relation to *malignant neoplasm of bone and articular cartilage* as advertised in the Government Notices Gazette of 6 November 2018.** |
| 68 & 69/2020 | trochanteric bursitis and gluteal tendinopathy | | **Amendment**  These instruments amend Statements of Principles Nos. 45 & 46 of 2015 concerning ***trochanteric bursitis and gluteal tendinopathy*** by:  ***For RH SoP*** ***(Instrument No. 68/2020)***   * revising factors (h) and (p) in clause 6 concerning significant disturbance of normal gait; and * deleting the definition of 'a significant disturbance of normal gait' in clause 9.   ***For BoP SoP*** ***(Instrument No. 69/2020)***   * inserting new factors (ga) and (na) in clause 6 concerning significant disturbance of normal gait.   **The determining of these Instruments finalises the investigation in relation to *trochanteric bursitis and gluteal tendinopathy* as advertised in the Government Notices Gazette of 18 June 2020.** |